Posted by Michael Wonder on 14 Dec 2024
First medicine to treat rare genetic disorder causing cysts and tumours
13 December 2024 - Oral medicine to treat two different conditions, rare von Hippel-Lindau disease and advanced clear cell renal cell carcinoma.
The EMA has recommended granting a conditional marketing authorisation in the European Union for Welireg (belzutifan) in adults with certain von Hippel-Lindau disease-associated tumours and in adults with previously treated advanced kidney cancer.
